Latest developments on daraxonrasib (RMC-6236)—an investigational pan-RAS inhibitor targeting RAS/RAF and related downstream signaling—include continued clinical reporting in RAS-mutant pancreatic cancer and additional preclinical work expanding where the mechanism may matter.
What’s new (recent)
- Pancreatic cancer clinical updates / 2026 coverage: Recent reporting highlights daraxonrasib’s activity and rationale in RAS-mutated pancreatic ductal adenocarcinoma (PDAC), including discussion of why newer “pan-RAS(ON)” strategies may overcome limitations seen with earlier KRAS-only drugs.[2]
- Phase 1/2 trial early activity mention (May 2026): An announcement describes daraxonrasib showing initial anti-tumor activity in RAS-mutant pancreatic cancer, based on results led by researchers at MD Anderson (phase 1/2).[10]
- Ongoing clinical significance of KRAS(variants) targeting: Daraxonrasib has been characterized as designed to inhibit “major forms” of oncogenic RAS(ON), with clinical readouts discussed in the context of ctDNA (RAS variant allele frequency reductions) and response/safety.[3]
Protein target / mechanism focus
- Daraxonrasib is positioned as a KRAS/pan-RAS pathway inhibitor that works by disrupting oncogenic RAS signaling and downstream pathways (e.g., RAF/MEK/ERK and PI3K/AKT), with downstream pathway suppression reported in KRAS-mutant settings.[1]
Where to look next (practical)
If you want, tell me whether you care more about (a) KRAS G12X pancreatic cancer trials, (b) broader “pan-RAS(ON)” preclinical findings, or (c) any specific sponsor/indication, and I’ll narrow to the most relevant recent headlines and primary sources.
Sources
Revolution Medicines’ daraxonrasib shows promising clinical results for metastatic pancreatic cancer, targeting previously undruggable...
www.chemdiv.comKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a wide array of KRAS mutations and shows promise against pancreatic and lung cancers. However, the efficacy and mechanisms of action of daraxonrasib in osteosarcoma (OS) remain unclear. We evaluated the effects of daraxonrasib on the viability,...
journals.plos.orgNew research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors. Results from the study were published in Cancer Immunology Research. It shows the potential for durable responses, laying the groundwork for future clinical trials and a...
www.eurekalert.orgThe FDA has granted breakthrough therapy designation to daraxonrasib for metastatic pancreatic cancer with KRAS G12 mutations.
rarecancernews.comA new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
longevitytoday.comTreatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.
www.onclive.comThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.eurekalert.orgDaraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.
www.onclive.comKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a ...
pmc.ncbi.nlm.nih.gov